Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group

被引:27
|
作者
Pasquino, AM
Pucarelli, I
Segni, M
Tarani, L
Calcaterra, V
Larizza, D
机构
[1] Univ Roma La Sapienza, Dipartimento Pediat, I-00161 Rome, Italy
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
[3] Univ Pavia, Dept Pediat Sci, I-27100 Pavia, Italy
关键词
D O I
10.1007/BF03347202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The main clinical feature of Turner syndrome (TS) is growth failure, with a mean spontaneous adult height ranging between 136 and 147 cm, according to the specific curves of various populations. Though a classical deficiency of GH has not been generally demonstrated, GH has been administered since 1980 in trials, using replacement doses just initially, with a subsequent trend to increase it. We report the outcome of GH therapy given at the fixed dose of 0.33 mg/kg/week in 60 TS girls observed until adult height; 59 untreated TS girls, matched for auxological, karyotypical characteristics and time of observation, born within the same decade served as controls to evaluate GH efficacy. The calculation of the gain in cm over PAH was performed on specific Italian Turner curves, as well as height evaluation as SD score and growth velocity. The same calculations were made using Lyon references and Tanner standards. The mean CA at the beginning of GH treatment was 10.9 +/- 2.76 yr (range 4.5-15.9). Mean adult height of treated group was 151 +/- 6.1 cm with a gain over the PAH calculated at start of therapy (142.9 +/- 5.3 cm) of 8.2 +/- 3.9 cm. Ns change was observed be-tween the PAH at first observation (143.6 +/- 7.0 cm) and adult height (144.3 +/- 5.6 cm) in the control group. Treatment was well tolerated, no relevant side effects were observed, glucose metabolism resulted no more affected than in untreated subjects, IGF-I levels remained within 2 SD. Our results in 60 TS girls, though the dose remained unchanged throughout the treatment, show a good response, characterized by a striking variability in each patient (mean gain in cm over PAH at adult height of 8.17 +/- 3.9, range 3-21 cm), and significant also in comparison with the control group. As the chronological age at start of therapy ranged between 4.5 to 15.9 yr, the results were further evaluated dividing the patients into two groups, according to the age, < or > 11 yr. Thirty girls were < 11 yr (mean 8.7 +/- 1.76 yr) and 30 were > 11 yr (mean 13.2 +/- 1.4 yr). The gain in cm over the PAH in each group was, respectively, 8.1 +/- 3.4 and 8.2 +/- 4.3 cm without any significant difference between the two groups, showing no negative correlation between the CA at the beginning of GH and the response to treatment. (c) 2005, Editrice Kurtis.
引用
收藏
页码:350 / 356
页数:7
相关论文
共 50 条
  • [41] Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome
    Mohamed, Sarar
    Alkofide, Hadeel
    Adi, Yaser A.
    Amer, Yasser Sami
    AlFaleh, Khalid
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
  • [42] Why Treat girls with Turner Syndrome with Growth Hormone? Growth and Beyond
    Ranke, Michael B.
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2015, 12 (04) : 356 - 365
  • [43] A decade of growth hormone treatment in girls with Turner syndrome in the UK
    Betts, PR
    Butler, GE
    Donaldson, MDC
    Dunger, DB
    Johnston, DI
    Kelnar, CJH
    Kirk, J
    Price, DA
    Wilton, P
    ARCHIVES OF DISEASE IN CHILDHOOD, 1999, 80 (03) : 221 - 225
  • [45] Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone
    Pasquino, AM
    Pucarelli, I
    Segni, M
    Matrunola, M
    Cerrone, F
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02): : 449 - 452
  • [46] Growth curves for Turkish Girls with Turner Syndrome: Results of the Turkish Turner Syndrome Study Group
    Darendeliler, Feyza
    Yesilkaya, Ediz
    Bereket, Abdullah
    Bas, Firdevs
    Bundak, Ruveyde
    Sari, Erkan
    Aydin, Banu Kucukemre
    Darcan, Sukran
    Dundar, Bumin
    Buyukinan, Muammer
    Kara, Cengiz
    Mazicioglu, Mumtaz M.
    Adal, Erdal
    Akinci, Aysehan
    Atabek, Mehmet Emre
    Demirel, Fatma
    Celik, Nurullah
    Ozkan, Behzat
    Ozhan, Bayram
    Orbak, Zerrin
    Ersoy, Betul
    Dogan, Murat
    Atas, Ali
    Turan, Serap
    Goksen, Damla
    Tarim, Omer
    Yuksel, Bilgin
    Ercan, Oya
    Hatun, Sukru
    Simsek, Enver
    Okten, Aysenur
    Abaci, Ayhan
    Doneray, Hakan
    Ozbek, Mehmet Nuri
    Keskin, Mehmet
    Onal, Hasan
    Akyurek, Nesibe
    Bulan, Kezban
    Tepe, Derya
    Emeksiz, Hamdi Cihan
    Demir, Korcan
    Kizilay, Deniz
    Topaloglu, Ali Kemal
    Eren, Erdal
    Ozen, Samim
    Demirbilek, Huseyin
    Abali, Saygin
    Akin, Leyla
    Eklioglu, Beray Selver
    Kaba, Sultan
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2015, 7 (03) : 183 - 191
  • [47] Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome
    Wooten, Nicole
    Bakalov, Vladimir K.
    Hill, Suvimol
    Bondy, Carolyn A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06): : 2109 - 2114
  • [48] Metabolic effects of oral versus Transdermal estrogen in growth hormone-treated girls with Turner syndrome
    Mauras, Nelly
    Shulman, Dorothy
    Hsiang, Helen Y.
    Balagopal, Prabhakaran
    Welch, Susan
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11): : 4154 - 4160
  • [49] Growth in girls with Turner syndrome
    Isojima, Tsuyoshi
    Yokoya, Susumu
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [50] The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome
    Menke, Leonie A.
    Sas, Theo C. J.
    Zandwijken, Gladys R. J.
    de Ridder, Maria A. J.
    Stijnen, Theo
    Keizer-Schrama, Sabine M. P. F. de Muinck
    Otten, Barto J.
    Wit, Jan M.
    CLINICAL ENDOCRINOLOGY, 2010, 73 (02) : 212 - 219